Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:CAPRNASDAQ:GLPGNASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$33.47-0.5%$31.27$23.42▼$62.58$1.94B0.73651,989 shs489,988 shsCAPRCapricor Therapeutics$11.15+9.5%$10.88$3.52▼$23.40$509.30M0.841.97 million shs2.64 million shsGLPGGalapagos$27.98-0.3%$27.57$22.36▼$31.23N/A0.07251,595 shs183,086 shsIRONDisc Medicine$54.50+0.7%$48.47$30.82▼$68.73$1.89B0.73339,865 shs1.06 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.53%-2.73%+8.56%+10.54%-22.81%CAPRCapricor Therapeutics+9.53%+34.99%+4.69%-3.04%+140.82%GLPGGalapagos-0.32%+2.04%-3.95%+9.90%+11.30%IRONDisc Medicine+0.68%+5.60%+20.79%+4.09%+25.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0239 of 5 stars3.41.00.04.21.80.81.9CAPRCapricor Therapeutics3.2179 of 5 stars4.63.00.00.01.80.80.6GLPGGalapagos0.3502 of 5 stars0.83.00.00.01.90.00.6IRONDisc Medicine2.0029 of 5 stars3.51.00.00.02.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6075.08% UpsideCAPRCapricor Therapeutics 3.13Buy$33.75202.69% UpsideGLPGGalapagos 1.50Reduce$25.33-9.46% DownsideIRONDisc Medicine 3.09Buy$96.7077.43% UpsideCurrent Analyst Ratings BreakdownLatest CAPR, IRON, AGIO, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.006/25/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/25/2025CAPRCapricor TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $29.006/24/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.006/23/2025CAPRCapricor TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$43.00 ➝ $22.006/17/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/17/2025IRONDisc MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$118.006/16/2025IRONDisc MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.006/13/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.006/11/2025IRONDisc MedicineRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/20/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M53.11N/AN/A$27.02 per share1.24CAPRCapricor Therapeutics$22.27M22.87N/AN/A$3.20 per share3.48GLPGGalapagos$298.31MN/A$0.73 per share38.54$47.57 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.98N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)CAPRCapricor Therapeutics-$40.47M-$1.42N/AN/AN/A-181.71%-62.42%-48.36%8/6/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)IRONDisc Medicine-$109.36M-$3.92N/AN/AN/AN/A-22.61%-21.07%8/6/2025 (Estimated)Latest CAPR, IRON, AGIO, and GLPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025GLPGGalapagos-$0.34N/AN/AN/A$80.13 millionN/A5/13/2025Q1 2025CAPRCapricor Therapeutics-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93CAPRCapricor TherapeuticsN/A6.556.55GLPGGalapagosN/A7.957.86IRONDisc Medicine0.0437.6537.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACAPRCapricor Therapeutics21.68%GLPGGalapagos32.46%IRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%CAPRCapricor Therapeutics10.50%GLPGGalapagos2.91%IRONDisc Medicine4.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableCAPRCapricor TherapeuticsN/A45.68 million40.88 millionOptionableGLPGGalapagos1,310N/AN/AOptionableIRONDisc Medicine3034.63 million33.17 millionNot OptionableCAPR, IRON, AGIO, and GLPG HeadlinesRecent News About These CompaniesDisc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of "Buy" by AnalystsJune 28 at 2:35 AM | marketbeat.comIRON - Disc Medicine Inc Ordinary Shares Ownership - MorningstarJune 27 at 11:11 PM | morningstar.comMLeerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price TargetJune 24, 2025 | msn.comSG Americas Securities LLC Grows Stake in Disc Medicine, Inc. (NASDAQ:IRON)June 21, 2025 | marketbeat.comLifesci Capital Forecasts Disc Medicine FY2025 EarningsJune 20, 2025 | americanbankingnews.comJean M. Franchi Sells 2,000 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockJune 19, 2025 | insidertrades.comGAMMA Investing LLC Grows Position in Disc Medicine, Inc. (NASDAQ:IRON)June 19, 2025 | marketbeat.comLifesci Capital Predicts Disc Medicine Q2 EarningsJune 19, 2025 | americanbankingnews.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) CFO Sells 2,000 Shares of StockJune 18, 2025 | marketbeat.comLifesci Capital Weighs in on Disc Medicine FY2025 EarningsJune 18, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Disc Medicine (NASDAQ:IRON)June 18, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Disc Medicine (NASDAQ:IRON)June 17, 2025 | marketbeat.comLifesci Capital Estimates Disc Medicine Q2 EarningsJune 17, 2025 | marketbeat.comDisc Medicine (NASDAQ:IRON) Stock Price Down 3% - Time to Sell?June 16, 2025 | marketbeat.comDisc Medicine (NASDAQ:IRON) Receives Outperform Rating from WedbushJune 16, 2025 | marketbeat.comRaymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy RatingJune 15, 2025 | msn.comDisc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual CongressJune 12, 2025 | globenewswire.comDisc Medicine (NASDAQ:IRON) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.comCantor Fitzgerald Forecasts Disc Medicine FY2026 EarningsJune 10, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 2,996 Shares of StockJune 10, 2025 | insidertrades.comWilliam Jacob Savage Sells 2,996 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockJune 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleAeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedBy Thomas Hughes | June 25, 2025View AeroVironment Will Hit New Highs This Year: Bull Flag ConfirmedCAPR, IRON, AGIO, and GLPG Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$33.47 -0.18 (-0.53%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$33.47 0.00 (-0.01%) As of 06/27/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$11.15 +0.97 (+9.53%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$11.16 +0.00 (+0.04%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Galapagos NASDAQ:GLPG$27.98 -0.09 (-0.32%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$27.99 +0.01 (+0.04%) As of 06/27/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Disc Medicine NASDAQ:IRON$54.50 +0.37 (+0.68%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$54.49 -0.01 (-0.02%) As of 06/27/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
